TORONTO–(BUSINESS WIRE)–Enigma Biomedical Group today announced a clinical research agreement
with Austin Health in Melbourne, Australia to support multiple projects
over the next several years. These research projects are for studies of
an early stage imaging agent (MK-6240) to be used in Positron Emission
Tomography (PET) scans for assessing the status and progression of
neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated
tau protein are a hallmark of several neurodegenerative diseases,
including Alzheimer’s disease.
As part of the agreement, Enigma will provide funding for various
research projects, and through its US entity Cerveau Technologies, Inc.,
will supply the MK-6240 precursor needed for the initiatives.
Lee Anne Gibbs, President of Enigma Biomedical Group said, “We are
excited to partner with Austin Health. This is an important step in
beginning a long-term relationship with Austin Health and a significant
step towards establishing an international network to facilitate
adoption of our technology and strategic initiatives.”
Professor Christopher Rowe, Director of Molecular Imaging Research said,
“These research projects will provide valuable insight into the status
and progression of NFTs in healthy subjects, subjects with mild
cognitive impairment and confirmed Alzheimer’s Disease. We appreciate
the support of Enigma Biomedical Group and value our ongoing
“At Cerveau, we are focused on providing information and technologies to
researchers and clinicians to improve brain health,” said Rick Hiatt,
President of Cerveau Technologies, Inc., and CEO of Enigma Biomedical
Group, “We are excited by the opportunity to work with Austin Health in
providing access to this novel imaging agent to the broader scientific
community and in continuing our past working relationship with Prof.
Rowe and Austin Health.”
About Austin Health
Austin Health is an internationally recognized leader in clinical
teaching and training. Austin LifeSciences brings together
internationally renowned research institutes and over 800 Austin Health
researchers. It is a world leader in the development and clinical
application of imaging for dementia and has one of the largest dementia
clinical trials sites in the world with over 30 trials currently
recruiting. Austin Health is the lead imaging site for national
multicenter dementia studies including the Australian Imaging Biomarkers
and Lifestyle study of Aging (AIBL).
About Enigma Biomedical Group
Toronto based Enigma Biomedical Group (EBG) enhances access to key
technologies with a focus on molecular imaging and medicine. EBG offers
a suite of services to the pharmaceutical industry and clinical research
community to accelerate drug development and global access. EBG partners
with academic institutions and universities to foster and broaden access
to novel research. More information can be found at http://www.enigmabiomedicalgroup.com/.
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical
Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to
globally develop diagnostics and technology that positively impact
patients with neurodegenerative disorders including Alzheimer’s disease.
Enigma Biomedical Group
Lee Anne Gibbs